Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
This trial is active, not recruiting.
|Condition||superficial bladder cancer|
|Start date||January 2008|
|End date||January 2013|
|Trial size||47 participants|
|Trial identifier||NCT00595088, BC-07-01.CTIL|
This study is designed to assess the efficacy and safety of DTA-H19/PEI given as six intravesical instillations of 20 mg of plasmid DNA complexed with PEI into the bladder of patients with intermediate risk superficial bladder cancer [recurrent stages Ta (low or high grade)and T1, (low grade) transitional cell carcinoma (TCC)] who have failed prior intravesical therapies including either Bacillus Calmette-Guérin (BCG) or chemotherapy. The primary efficacy objective is to determine the effect of DTA-H19/PEI on the prevention of new tumors after the induction course of 6 weekly intravesical administrations of investigational product assessed 8 to 10 weeks after the start of treatment. Secondary objectives include assessing the ablative effect of DTA-H19/PEI on a marker tumor, safety assessed by the incidence and severity of adverse events, determining the long-term (46 weeks) continued rates of absence of bladder cancer, and time to tumor recurrence in those patients who had a complete response (CR) after the induction course.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Phoenix, AZ||BCG Oncology||no longer recruiting|
|Haifa, Israel||Bnai Zion Medical Center||no longer recruiting|
|Holon, Israel||Edith Wolfson Medical Center||no longer recruiting|
|Jerusalem, Israel||Hadassah and Hebrew University Medical Center||no longer recruiting|
|Kfar Saba, Israel||Meir Medical Center||no longer recruiting|
|Zrifin, Israel||Assaf Harofeh||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Complete Tumor Response Defined as the Absence of New Tumors
time frame: 9 Weeks
Time to Tumor Recurrence
time frame: 46 Weeks
Ablative Effect on a Marker Tumor
time frame: 9 weeks
time frame: 9 weeks
Male or female participants at least 18 years old.
- Provide written informed consent.
- Have intermediate-risk recurrent superficial TCC of the bladder defined as Stage Ta (low or high grade) or T1 (but with penetration into no more than ½ of the lamina propria), low grade (grade 1 or grade 2), as confirmed by histopathology, and have not recurred within 3-months of a complete course of a prior acceptable therapy (i.e., 6-weekly intravesical administrations of BCG or standard adjuvant treatment with thiotepa, doxorubicin, epirubicin, valrubicin, or mitomycin C).
- Have complete resection of all papillary tumors with the exception of a single superficial papillary tumor that is appropriate to be a marker tumor (<1 cm in diameter).
- Have ≥ 2 tumor and ≤ 7 tumors visible during cystoscopy and no tumor larger than 3 cm in diameter. If only one tumor is present, it must be large enough to obtain a biopsy specimen adequate to determine the tumor stage and grade and leave a marker tumor.
- Have at least one tumor specimen resected before the start of the study that was positive for H19 expression by ISH. H19 expression positive is defined as >= 60 % of the tumor cells in the specimen expressing H19 at a moderate staining intensity.
- Have failed at least one prior standard intravesical treatment including chemotherapy with mitomycin C, thiotepa, valrubicin, doxyrubicin, or epirubicin, or immunotherapy with BCG. Failure after treatment with chemotherapy is defined as recurrent disease after at least one intravesical instillation of drug. Failure after treatment with BCG is defined as intolerance to treatment such that treatment was discontinued or after having received 6 or more BCG instillations there is recurrent or persistent disease 3 or more months after initiation of BCG treatment.
- Have a Karnofsky's performance status of greater than or equal to 60%.
- Have adequate bone marrow reserve: Hemoglobin > 10 g/dL, WBC greater than or equal to 3000/mm3, and platelets > 100,000 /mm3.
- Have adequate renal function with serum creatinine < 1.5 x the laboratory upper limit of normal (ULN).
- Have adequate liver function with serum biliru¬bin, AST/SGOT and ALT/SGPT < 2 times the laboratory ULN.
- Be at least 18 years of age.
- If male, agree to use a condom, if sexually active, and if female, agree to practice one of the acceptable methods of birth control or be surgically sterile or postmenopausal (greater than 1 year post last menstrual cycle.
- Have current diagnosis or history of Stage T1 (high grade) or Stage T2 or higher or CIS.
- Have severe concomitant disease that might limit compliance or completion of the protocol.
- Have a tumor in a diverticulum, in the prostatic urethra, or covering the ureteral orifice.
- Have any other malignancy that might impact 5-year survival or might be potentially confused with TCC.
- Have congenital or acquired immune deficiencies.
- Be receiving cytotoxic drugs or corticosteroids.
- Have received intravesical therapy within 8 weeks prior to study entry.
- Have received radiation therapy for their bladder cancer at any time or any other conditions including pelvic irradiation for any condition within 4 months prior to study entry.
- Have active infections (including urinary tract infections) defined as viral, bacterial, or fungal infections requiring therapy, HIV-positive status, concurrent febrile illness, or gross hematuria.
- Have biopsy, TUR, or traumatic catheterization within 14 days of start of treatment.
- If female, be pregnant or breast feeding.
- Have participated in any therapeutic research study within the last 8 weeks.
- Have participated in any other gene therapy study including patients who have received DTA-H19/PEI in the past.
|Official title||Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer|
|Principal investigator||Donald Lamm, MD|
|Description||DTA-H19, is a doubled stranded DNA plasmid that carries the gene for the diphtheria toxin A (DT-A) chain under the regulation of the H19 promoter sequence. This is a Patient-Oriented, Targeted Therapy as DT-A chain expression is triggered by the presence of H19 transcription factors that are upregulated in tumor cells. The selective initiation of toxin expression results in selective tumor cell destruction via inhibition of protein synthesis in the tumor cell, enabling highly targeted cancer treatment.|
Call for more information